Sreekanth Vemulapalli1, Luqin Deng2, Manesh R Patel3, Meredith L Kilgore2, W Schuyler Jones3, Lesley H Curtis3, Marguerite Ryan Irvin2, Laura P Svetkey4, Daichi Shimbo5, David A Calhoun6, Paul Muntner2. 1. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC. Electronic address: sreekanth.vemulapalli@duke.edu. 2. School of Public Health, University of Alabama at Birmingham, Birmingham, AL. 3. Duke Clinical Research Institute, Duke University Medical Center, Durham, NC. 4. Department of Medicine, Division of Nephrology, Duke University Medical Center, Durham, NC. 5. Division of Cardiology, Columbia University, New York, NY. 6. Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL.
Abstract
BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is associated with an increased risk of adverse cardiovascular outcomes. We studied the frequency and intensity of care for aTRH among participants aged 65 years and older in the US-based REGARDS study linked with Medicare claims. METHODS: Blood pressure (BP) was measured twice and averaged. aTRH was defined by the use of ≥3 classes of antihypertensive medication and uncontrolled BP (UaTRH, systolic/diastolic BP ≥140/90 mmHg), or ≥4 classes with controlled BP (CaTRH). Participants were categorized as not having aTRH (no aTRH), CaTRH or UaTRH. RESULTS: Among 4650 participants with hypertension, 468 (10.1%) had UaTRH, 247 (5.3%) had CaTRH, and 3935 (84.6%) had hypertension but did not have aTRH. For hypertension-related visits, those with UaTRH saw primary care physicians and cardiologists more frequently than those without aTRH (mean primary care visits per year: 2.77 vs 2.27, P<.001; cardiologists: 0.50 vs 0.35, P=.014). Among those with UaTRH, CaTRH, and no aTRH, respectively 73.5%, 68.0%, and 67.5% had >1 hypertension-related visit per year. Among those with UaTRH, males vs females (prevalence ratio=0.78; 95% CI 0.69-0.89), whites vs blacks (0.88; 95% CI 0.78-0.99), and current smokers vs non-smokers (0.66; 95% CI 0.48-0.89) were less likely to receive >1 hypertension-related visit per year. Diagnostic intensity, measured by testing for end organ damage and secondary hypertension, was similar between groups. CONCLUSIONS: Many people with UaTRH are not seen more than once per year for hypertension and may benefit from increased care.
BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is associated with an increased risk of adverse cardiovascular outcomes. We studied the frequency and intensity of care for aTRH among participants aged 65 years and older in the US-based REGARDS study linked with Medicare claims. METHODS: Blood pressure (BP) was measured twice and averaged. aTRH was defined by the use of ≥3 classes of antihypertensive medication and uncontrolled BP (UaTRH, systolic/diastolic BP ≥140/90 mmHg), or ≥4 classes with controlled BP (CaTRH). Participants were categorized as not having aTRH (no aTRH), CaTRH or UaTRH. RESULTS: Among 4650 participants with hypertension, 468 (10.1%) had UaTRH, 247 (5.3%) had CaTRH, and 3935 (84.6%) had hypertension but did not have aTRH. For hypertension-related visits, those with UaTRH saw primary care physicians and cardiologists more frequently than those without aTRH (mean primary care visits per year: 2.77 vs 2.27, P<.001; cardiologists: 0.50 vs 0.35, P=.014). Among those with UaTRH, CaTRH, and no aTRH, respectively 73.5%, 68.0%, and 67.5% had >1 hypertension-related visit per year. Among those with UaTRH, males vs females (prevalence ratio=0.78; 95% CI 0.69-0.89), whites vs blacks (0.88; 95% CI 0.78-0.99), and current smokers vs non-smokers (0.66; 95% CI 0.48-0.89) were less likely to receive >1 hypertension-related visit per year. Diagnostic intensity, measured by testing for end organ damage and secondary hypertension, was similar between groups. CONCLUSIONS: Many people with UaTRH are not seen more than once per year for hypertension and may benefit from increased care.
Authors: Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho Journal: Circulation Date: 2012-02-29 Impact factor: 29.690
Authors: George Howard; Ron Prineas; Claudia Moy; Mary Cushman; Martha Kellum; Ella Temple; Andra Graham; Virginia Howard Journal: Stroke Date: 2006-03-23 Impact factor: 7.914
Authors: Marguerite R Irvin; John N Booth; Daichi Shimbo; Daniel T Lackland; Suzanne Oparil; George Howard; Monika M Safford; Paul Muntner; David A Calhoun Journal: J Am Soc Hypertens Date: 2014-03-15
Authors: Dharam J Kumbhani; P Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Kevin Crowley; Shinya Goto; E Magnus Ohman; George L Bakris; Todd S Perlstein; Scott Kinlay; Deepak L Bhatt Journal: Eur Heart J Date: 2012-11-09 Impact factor: 29.983
Authors: David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Brent M Egan; Yumin Zhao; Jiexiang Li; W Adam Brzezinski; Thomas M Todoran; Robert D Brook; David A Calhoun Journal: Hypertension Date: 2013-08-05 Impact factor: 10.190
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Elizabeth do Espirito Santo Cestário; Letícia Aparecida Barufi Fernandes; Luiz Tadeu Giollo-Júnior; Jéssica Rodrigues Roma Uyemura; Camila Suemi Sato Matarucco; Manoel Idelfonso Paz Landim; Luciana Neves Cosenso-Martin; Lúcia Helena Bonalume Tácito; Heitor Moreno; José Fernando Vilela-Martin; Juan Carlos Yugar-Toledo Journal: Trials Date: 2018-02-12 Impact factor: 2.279